Table 1. Baseline characteristics of newly diagnosed people with human immunodeficiency virus during 2012 - 2020.
| Characteristics | Year | Total (n = 248) | P-valuea | |||
|---|---|---|---|---|---|---|
| 2012 - 2014 (n = 59) | 2015 - 2017 (n = 104) | 2018 - 2020 (n = 85) | ||||
| Age (median, IQR) | 36 (28 - 48) | 30 (24 - 46) | 29 (26 - 39) | 31 (25 - 44) | 0.148 | |
| Male, n (%) | 55 (93.2) | 99 (95.2) | 80 (94.1) | 234 (94.4) | 0.832 | |
| Comorbidity, n (%) | 9 (15.3) | 18 (17.3) | 8 (9.4) | 35 (14.1) | 0.288 | |
| Diabetes mellitus | 1 (1.7) | 5 (4.8) | 2 (2.4) | 8 (3.2) | 0.594 | |
| Hypertension | 4 (6.8) | 7 (6.7) | 1 (1.2) | 12 (4.8) | 0.139 | |
| Chronic hepatitis B | 1 (1.7) | 5 (4.8) | 2 (2.4) | 8 (3.2) | 0.594 | |
| Chronic hepatitis C | 1 (1.7) | 1 (1.0) | 2 (2.4) | 4 (1.6) | 0.825 | |
| Liver cirrhosis | 0 (0.0) | 1 (1.0) | 0 (0.0) | 1 (0.4) | 0.999 | |
| Solid organ tumor | 0 (0.0) | 1 (1.0) | 2 (2.4) | 3 (1.2) | 0.611 | |
| Lymphoma | 3 (5.1) | 0 (0.0) | 0 (0.0) | 3 (1.2) | 0.013 | |
| Resistance mutation, n (%) | 9 (15.3) | 10 (9.6) | 11 (12.9) | 30 (12.1) | 0.545 | |
| Any Mutation, n (%) | 35 (59.3) | 61 (58.7) | 54 (63.5) | 150 (60.5) | 0.775 | |
| Laboratory results (median, IQR) | ||||||
| White blood cell count, /mm3 | 5,070 (3,990 - 6,210) | 5,090 (4,048 - 6,220) | 5,170 (4,125 - 6,770) | 5,120 (4,073 - 6,400) | 0.470 | |
| CD4+ T cell count, /mm3 | 264 (60 - 473) | 261 (124 - 419) | 231 (84 - 341) | 251 (113 - 399) | 0.177 | |
| HIV RNA, copies/mL | 64,407 (25,508 - 183,076) | 38,717 (11,636 - 133,834) | 49,789 (12,080 - 177,297) | 49,041 (13,359 - 160,000) | 0.417 | |
Values are counts (%) or median (interquartile range) as indicated.
aKruskal-Wallis test for continuous variables, Chi-square or Fisher’s exact test for categorical variables.
IQR, interquartile range; HIV, human immunodeficiency virus.